Musk's $1 trillion pay, a price cut for obesity drugs, Target's in-store woes and more in Morning Squawk

Tesla shareholders approved Elon Musk's controversial near $1 trillion pay package, increasing his control and linking compensation to ambitious targets, including 1 million Optimus robots. Concurrently, major AI stocks like Nvidia and Microsoft led a broader market sell-off amid concerns over elevated valuations and a significant surge in October layoffs, signaling economic deceleration. In healthcare, President Trump secured deals with Eli Lilly and Novo Nordisk to drastically cut obesity drug prices, with Medicare coverage beginning in 2026. Separately, OpenAI projects over $20 billion in annualized revenue but faces uncertainty funding its $1.4 trillion infrastructure deals, with advisors ruling out federal bailouts.

Analysis

The broader market experienced a sell-off, with the Nasdaq Composite dropping 1.9% and the Dow Jones Industrial Average losing 400 points, primarily driven by investor concerns over elevated valuations in artificial intelligence stocks. Shares of Nvidia, Advanced Micro Devices, and Microsoft all closed lower, reflecting this cautious sentiment. This market apprehension was exacerbated by a significant deterioration in the labor market, as October saw a 183% surge in layoffs month-over-month and a 175% increase year-over-year, with economists anticipating a 60,000 job decline.

In the AI sector, Tesla shareholders approved CEO Elon Musk's nearly $1 trillion pay plan, increasing his voting power to 25% and tying compensation to ambitious milestones, including the delivery of 1 million Optimus robots, which are currently unavailable. Concurrently, OpenAI projects over $20 billion in annualized revenue this year but faces uncertainty regarding funding for its $1.4 trillion infrastructure deals, with a "no federal bailout" stance confirmed by advisors.

Pharmaceutical giants Eli Lilly and Novo Nordisk will face significant price cuts on obesity drugs following agreements with President Trump, though Medicare coverage for GLP-1s starting mid-2026 could expand market access. Separately, Target is overhauling its e-commerce fulfillment strategy by limiting stores used for online order processing to improve its in-store customer experience, addressing recent complaints about operational inefficiencies.

Key Decisions for Investors

• Investors should re-evaluate their exposure to high-valuation AI and tech stocks given the recent market sell-off and deteriorating labor market data, considering defensive positioning.
• Tesla's approved executive compensation, tied to ambitious AI and robotics milestones, introduces both significant long-term growth potential and considerable execution risk, warranting close monitoring of operational achievements.
• The new drug pricing agreements for Eli Lilly and Novo Nordisk, coupled with Medicare coverage for GLP-1s, signal increasing regulatory influence on pharmaceutical pricing but also potential for expanded market penetration.
• Target's operational adjustments to its e-commerce fulfillment strategy highlight ongoing retail logistics challenges; investors should monitor the effectiveness of these changes on both customer experience and profitability.